

19



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



11 Publication number:

0 528 034 A1

12

**EUROPEAN PATENT APPLICATION**  
published in accordance with Art.  
158(3) EPC

21 Application number: 91909364.1

51 Int. Cl.5: A61K 37/22

22 Date of filing: 17.05.91

86 International application number:  
PCT/JP91/00664

87 International publication number:  
WO 91/17766 (28.11.91 91/27)

30 Priority: 18.05.90 JP 126936/90

43 Date of publication of application:  
24.02.93 Bulletin 93/08

84 Designated Contracting States:  
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

71 Applicant: TOKYO TANABE COMPANY  
LIMITED  
2-6, Nihonbashi-Honcho 2-chome  
Chuo-ku Tokyo 103(JP)

72 Inventor: KURASHIMA, Kazuyoshi, 20-21,  
Asahi-machi 2-chome  
Kanazawa-shi  
Ishikawa 920(JP)

74 Representative: Calamita, Roberto  
Frank B. Dehn & Co., Imperial House, 15-19  
Kingsway  
London WC2B 6UZ (GB)

54 REMEDY FOR ASTHMA.

57 A remedy for asthma containing as the active ingredient a lung surface activator which can inhibit bronchoconstriction induced by allergic bronchoconstriction.

EP 0 528 034 A1

## TECHNICAL FIELD

This invention relates to an antasthmatic containing a pulmonary surface active material (hereinafter abridged as PSF) as an effective ingredient.

## BACKGROUND ART

It is generally realized that bronchial asthma is a very complex syndrome with various causes and its dominating clinical symptoms are not constant.

On the other hand, PSF is specially evaluated as a therapeutic agent for respiratory distress syndrome which has a high mortality. The main function of PSF is to reduce surface tension (i.e. free energy of the surface per unit area) of the air-liquid interface and thereby provides mechanical stability to alveolar units. PSF exists not only in alveoli but also in airways and stabilizes bronchi, thereby protecting bronchi against radius changes with lung volume. Further, PSF contributes importantly to pulmonary function, including reduction of breathing work and control of fluid transudation which protects against development of pulmonary edema. In fact, in edema induced artificially by increasing alveolar surface tension, an exogenous PSF can be administered to reduce protein permeability in alveoli of premature lambs. In asthmatic attack, mucus secretion increases and clearance of mucosal cilia is disturbed. Increases of mucus secretion and transudation of proteinous fluid may inhibit surfactant activity in small airways and alveoli. Increased surface tension and transudation causes occlusion by the fluid which transuded during exhalation in the airways closest to the alveoli. It is considered that if surface activity has something to do with the peripheral airways in asthmatic attack, administration of PSF have some therapeutic effects in asthmatic attack. In practice, however, the efficacy of PSF as an antasthmatic has not been known yet.

The inventor has eagerly researched for a drug useful as an antasthmatic and found that PSF has marked therapeutic effects in guinea pigs with antigen-induced bronchoconstriction as a model of bronchial asthma and, in fact, in patients with asthma, leading to the present invention.

## DISCLOSURE OF THE INVENTION

This invention provides an antasthmatic containing PSF as an effective ingredient.

As PSF in the antasthmatic of the present invention, can be used various known materials containing phospholipid by 40 w/w% or more as a whole, including phosphatidylcholine or choline phosphoglyceride as a main component. In detail, as PSF used in the present invention, can be listed (i) a surface active material which contains phospholipids, neutral lipids, total cholesterol, carbohydrates and proteins, of origin of mammalian pulmonary tissue, respectively at 75.0-95.5 w/w%, 1.8-14.0 w/w%, 3.0 w/w% or less, 0.1-1.5 w/w%, and 5.0 w/w% or less of total weight of the dried final product (Japanese Patent Publication No. 61-9925); (ii) a pulmonary surface active pharmaceutical composition mainly consisting of dipalmitoylphosphatidyl choline and fatty alcohols (Japanese Unexamined Patent Laid-open No. 57-99524); (iii) a surface active material (referred to as Surfactant TA in the following) containing phospholipids, neutral lipids, total cholesterol, free fatty acids, carbohydrates and proteins, of origin of mammalian pulmonary tissue, respectively at 68.6-90.7 w/w%, 0.3-13.0 w/w%, 0.0-8.0 w/w%, 1.0-27.7 w/w%, 0.1-2.0 w/w% and 0.0-3.5 w/w% of the total dry weight (Japanese Patent Publication No. 61-9924); (iv) a synthetic surface active material mainly containing phospholipid phosphatidyl choline and unsaturated fatty acids or their esters, the proportion of the phosphatidyl choline being 55-80 w/w% of the total (Japanese Unexamined Patent Laid-open No. 58-135813); (v) a pulmonary surface active material containing phospholipids at 80 w/w% or more of the total and containing substantially no proteins (Japanese Unexamined Patent Laid-open No. 58-164513); (vi) a pulmonary surface active material containing phospholipids, neutral lipids, cholesterol and carbohydrates, extracted from mammalian lung, in the component ratios of 70-95 w/w%, 1-10 w/w%, 3.0 w/w% or less, and 0.3 w/w% or less, respectively, after drying, and containing substantially no proteins (Japanese Patent Unexamined Laid-open No. 58-183620); (vii) a synthetic pulmonary surface active material containing phospholipid phosphatidyl choline and cardiolipin as main ingredients, the ratio of the phosphatidyl choline being 55-80 w/w% of the total (Japanese Patent Publication No. 1-29171); (viii) a pulmonary surfactant containing 40-45 w/w% of dipalmitoylphosphatidyl choline, 5-10 w/w% of dipalmitoylphosphatidylglycerol and 50 w/w% of sugars (Japanese Patent Publication No. 1-13690); (ix) a synthetic pulmonary surface active material (referred to as Surfactant CL in the following) containing 80-95 w/w% of phosphatidyl choline, cardiolipin and/or phosphatidyl glycerol, as phospholipids, 5-20 w/w% of neutral lipids and 0-10 w/w% of fatty acids (Japanese Unexamined Patent Laid-open No. 59-95219, Journal of Japan Surface Medicine Society, Vol.14, No.1: p.59, 1983); (x) a surfactant (referred to as Synthetic Surfactant X1

in the following) mainly containing choline phosphoglyceride, acid phospholipids, fatty acids, and mammalian lung-derived lipoproteins, respectively at 50.6-85.0 w/w%, 4.5-37.6 w/w%, 4.6-24.6 w/w% and 0.1-10.0 w/w% (Japanese Unexamined Patent Laid-open No. 59-164724); (xi) a synthetic pulmonary surface active material containing 55-80 w/w% of phosphatidyl choline having 2 residues of saturated straight chain fatty acid, 10-35 w/w% of phosphatidyl glycerol having 2 residues of saturated straight chain fatty acid and 5-20 w/w% of neutral lipids (Japanese Unexamined Patent Laid-open No. 59-181216); (xii) a mixture of agonists containing 40-70 % of phospholipids, less than 1.5 % of proteins, 10-40 % of cholesterol and 5-30 % of neutral lipids (Japanese Unexamined Patent Laid-open No. 60-237023); (xiii) a synthetic surfactant (referred to as Synthetic Surfactant X2 in the following) mainly containing choline phosphoglyceride, acid phospholipids and fatty acids respectively at 53.9-87.8 w/w%, 4.8-38.2 w/w% and 7.0-26.2 w/w% of the total weight (Japanese Patent Publication No. 2-8768); (xiv) a material (referred to as Surfactant CK in the following) consisting of lipids extracted from porcine alveolar washing solution to which calcium chloride is added (Journal of Japan Surface Medicine Society, Vol.12, No.1, p.1, 1981 and Vol.14, No.2, p.212, 1983); (xv) a synthetic pulmonary surface active material containing a mixture of 3 components system including dipalmitoyl phosphatidyl choline, distearoyl phosphatidyl choline and soybean lecithin (Japanese Patent Publication No. 64-9292); (xvi) a pulmonary arterial surfactant originating from animal comprising a polar lipid fraction and a protein fraction, which is composed of at least 98.5 w/w% of the polar lipids, and mainly composed of at least 95 % of a mixture of phospholipids (Japanese Unexamined Patent Laid-open No. 64-63526); (xvii) a synthetic pulmonary surface active material containing the pulmonary surface active material proteins described in and manufactured with the pulmonary surface active material proteins described in Japanese Kohyo No. 62-501122, Japanese Kohyo No. 62-501792, Japanese Kohyo No. 63-503222, Japanese Kohyo No. 1-501282, Japanese Unexamined Patent Laid-open No. 2-424, Japanese Unexamined Patent Laid-open No. 2-6405, Japanese Unexamined Patent Laid-open No. 2-53798, Japanese Unexamined Patent Laid-open 2-279628, Japanese Kohyo No. 2-502917, Japanese Unexamined Patent Laid-open No. 3-44332 and Japanese Unexamined Patent Laid-open No. 3-90033, or, in addition, pulmonary surface active material proteins produced by gene recombination techniques; and (xviii) a natural PSF or a product prepared from it, such as Alveofact (tradename, See Eur. J. Pediatr. (1990) 149: 280-283; and LIPIDS, Vol.18, No.8 (1983) 522-529) obtained from bovine alveoli and comprising phospholipids, cholesterol, hydrophobic surface active proteins, free fatty acids, triglycerides and calcium; Infasurf (tradename); Curosurf (tradename); and Humansurf (tradename) obtained from human waters; (xix) a synthetic PSF such as Exosurf (tradename) comprising Surfactant CK, dipalmitoyl phosphatidyl choline, hexadecanol, Tyloxapol (formaldehyde polymer with oxirane and 4-(1,1,3,3-tetramethylbutyl)phenol) and sodium chloride; ALEC (tradename) comprising 7 parts of dipalmitoyl phosphatidyl choline and 3 parts of phosphatidyl glycerol; Dry Surfactant; and Liposomalform.

Also, a dispersing concentration of PSF in a range of 0.1-100.0 mg/ml, preferably 1-50 mg/ml, and more preferably 2-40 mg/ml, is suitable.

#### BRIEF DESCRIPTION OF DRAWINGS

Fig. 1 is a schematic view of an apparatus used as a body plethysmograph for a guinea pig;  
 Fig. 2 is a graph explaining calculations of Cdyn and RL;  
 Fig. 3 is a graph relating to Surfactant TA, showing percent changes in pressure at airway opening (Pao) from the baseline after antigen challenge in three groups of experimental animals;  
 Fig. 4 is a graph relating to Surfactant TA, showing percent changes in dynamic compliance of lung (Cdyn) from the baseline;  
 Fig. 5 is a graph relating to Surfactant TA, showing percent changes in pulmonary resistance (RL) from the baseline;  
 Fig. 6 is a graph showing effects of inhalation of Surfactant TA for 90 seconds against bronchoconstriction induced by histamine;  
 Fig. 7 is a graph relating to ALEC, showing percent changes in pressure at airway opening (Pao) after antigen challenge in three groups of experimental animals;  
 Fig. 8 is a graph relating to ALEC, showing percent changes in dynamic compliance of lung (Cdyn) from the baseline;  
 Fig. 9 is a graph relating to ALEC, showing percent changes in pulmonary resistance (RL) from the baseline;  
 Fig. 10 is a graph relating to Exosurf, showing percent changes in pressure at airway opening (Pao) after antigen challenge in three groups of experimental animals;

Fig. 11 is a graph relating to Exosurf, showing percent changes in dynamic compliance of lung (Cdyn) from the baseline;

Fig. 12 is a graph relating to Exosurf, showing percent changes in pulmonary resistance (RL) from the baseline;

Fig. 13 is a graph relating to Alveofact, showing percent changes in pressure at airway opening (Pao) after antigen challenge in three groups of experimental animals;

Fig. 14 is a graph relating to Alveofact, showing percent changes in dynamic compliance of lung (Cdyn) from the baseline;

Fig. 15 is a graph relating to Alveofact, showing percent changes in pulmonary resistance (RL) from the baseline;

Fig. 16 is a graph relating to Surfactant CK, showing percent changes in pressure at airway opening (Pao) after antigen challenge in three groups of experimental animals;

Fig. 17 is a graph relating to Surfactant CK, showing percent changes in dynamic compliance of lung (Cdyn) from the baseline;

Fig. 18 is a graph relating to Surfactant CK, showing percent changes in pulmonary resistance (RL) from the baseline;

Fig. 19 is a graph relating to Humansurf, showing percent changes in pressure at airway opening (Pao) after antigen challenge in three groups of experimental animals;

Fig. 20 is a graph relating to Humansurf, showing percent changes in dynamic compliance of lung (Cdyn) from the baseline; and

Fig. 21 is a graph relating to Humansurf, showing percent changes in pulmonary resistance (RL) from the baseline.

[Effects on a bronchial experimental model]

Preparation of asthma model

Preparation of high titer anti-ovalbumin antiserum

Guinea pig homocytotropic antiserum was made by the modified method of Santives et al (Santives T, Roska AK, Henly G, Moore VL, Fink JN, Abramoff P: Immunologically induced lung disease in guinea pig; J Allergy Clin Immunol 1976; 57: 582-594). A dose of 500 µg ovalbumin (OA) was emulsified in complete Freund's adjuvant and administered intradermally into each guinea pig at 5 different areas, i.e., bilateral axilla, bilateral inguinal region and neck. Boostering was carried out in the same manner 2 weeks later. The serum was collected 2 weeks after the booster, pooled and kept frozen until use.

Induction of experimental asthma

Guinea pigs were passively sensitized with 1 ml/kg of the above-described antiserum administered intraperitoneally. Twelve to 24 h after the passive sensitization, the guinea pigs were anesthetized with an intraperitoneal injection of 75 mg/kg pentobarbital sodium. They were placed in the supine position, the trachea was cannulated with a polyethylene tube (outer diameter 2.5 mm; inner diameter 2.1 mm), and one jugular vein was cannulated for the administration of drugs. The animals were artificially ventilated by a small animal ventilator (Model 1680, Harvard Apparatus, South Natick, MA) adjusted to a tidal volume of 10 ml/kg at a rate of 60 breaths/min. Mechanical dead space in this system was 0.5 ml. When all the above procedures were completed, the animals were given 60 mg/kg diphenhydramine hydrochloride intraperitoneally to block the action of histamine completely, and overinflated by 2 times of tidal volume by clamping the outlet port of the respirator. Ten minutes later, the animals were challenged with nebulized ovalbumin (antigen) dissolved in saline (1 mg/ml) without interrupting the artificial ventilation. The ovalbumin aerosol was generated for 30 seconds by an apparatus equipped with an ultrasonic nebulizer, developed for small animal experiments.

Pulmonary surface active material

Surfactant TA (Surfacten, Tokyo Tanabe Company, Ltd., Tokyo; 120 mg lyophilized pulmonary surfactant lipid in a vial) was suspended in warmed (37°C) saline to give a lipid concentration of 10 and 20 mg/ml.

Other drugs used were as follows: ovalbumin (Sigma, St. Louis, MO), complete Freund's adjuvant (Difco Laboratories, Detroit, MI), diphenhydramine HCl (Sigma, St. Louis, MO), pentobarbital sodium solution (Abbott Laboratories, North Chicago, IL), histamine dihydrochloride (Wako pure chemical industries, Osaka, Japan).

## Measurements

As shown in Fig. 1, pressure at airway opening (Pao), lateral pressure of tracheal tube, was measured using a differential pressure transducer (Model TP-603T, Nihon Koden, Tokyo Japan). In addition, esophageal pressure (Peso) was measured by a water-filled polyethylene catheter (outer diameter 1.4 mm; inner diameter 1.0 mm) which was inserted into the esophagus and connected to a low-pressure transducer (Model MPU-0.1A, Nihon Koden). Thereafter, the guinea pigs were kept in a small airtight plastic box, and a flow rate ( $\dot{V}$ ) of the air was measured with a Lilly-type pneumatograph (Model TV241T, Nihon Koden) and a low-pressure transducer (Model TP-602T, Nihon Koden) placed at the small window of the box. The flow rate was electronically integrated and the ventilation volume (V) was measured. These parameters,  $\dot{V}$ , V, Pao and Peso, were recorded continuously on a multi-channel recorder (Model P-0770c, Nihon Koden). According to the methods described by Amdur Mo, and Mead J: Mechanics of respiration in unanesthetized guinea pigs; Am J Physiol 1958; 192: 346-368, dynamic compliance of lung (Cdyn) and pulmonary resistance (RL) were calculated by the equations shown in Fig. 2.

Cdyn was divided by body weight (kg), and RL used was the value multiplied by the body weight. In order to compare the changes in peripheral airway and those in primary bronchus, the ratio of Cdyn and reciprocal RL (1/RL) to the baseline were calculated.

Pao was measured continuously, and Cdyn and RL were measured shortly before the antigen inhalation (base line), at its peak, 18 and 23 minutes after the antigen challenge. The changes in these values at each time were expressed as percent changes of the baseline value, i.e., %Pao, %Cdyn, %1/RL, respectively. Recovery rate was determined as percent change of the value at 23 minutes to that at 18 minutes.

## Protocol

A total of 27 guinea pigs were studied according to the following protocol. After the administration of diphenhydramine hydrochloride, measurements of respiratory function were performed (baseline). Then, the animals were challenged with nebulized ovalbumin. About 14 minutes later when the Pao reached its maximum value, second measurements of respiratory function were performed. At 18 minutes later when the bronchoconstriction became sustained phase where the rate of decrease in Pao became slow, third measurements of respiratory function were performed (before administering PSF). Twenty minutes later, either Surfactant TA 10 mg/ml (a PSF 10 mg/ml treated group, n=9), 20 mg/ml (a PSF 20 mg/ml treated group, n=9), or saline (a control group, n=9) was inhaled for 90 minutes. Inhalants were given by the ultrasonic nebulizer described above. The median aerodynamic diameters of the particles of saline, PSF 10 mg/ml, PSF 20 mg/ml produced by the nebulizer were  $3.59 \pm 1.96 \mu\text{m}$  (mean  $\pm$  SD),  $3.64 \pm 1.87 \mu\text{m}$ ,  $3.63 \pm 1.98 \mu\text{m}$ , respectively. Fourth measurements of respiratory function were performed 23 minutes after ovalbumin challenge (1.5 minutes after the end of PSF or saline inhalation).

## Histamine-induced bronchoconstriction

Other guinea pigs (n=10) were anesthetized and artificially ventilated as described above, and then, ascending doses of histamine were intravenously administered at 5 minute intervals without interrupting the ventilation. In 5 guinea pigs, inhalant of Surfactant TA 20 mg/ml was inhaled for 90 seconds, 10 minutes before the histamine provocation. As the control, inhalant of saline was given to the other 5 guinea pigs in the same manner.

## Statistical Analysis

Data are presented as mean  $\pm$  SEM, and the statistical differences were determined by Mann-Whitney's U test, taking a P value of 0.05 or less as significant.

## Results

## Effects of PSF inhalation in the asthmatic model

Baseline values of Pao, Cdyn, RL in all the experimental animals were  $10.5 \pm 0.27$  cmH<sub>2</sub>O,  $1.33 \pm 0.07$  ml/cmH<sub>2</sub>O\*kg,  $6.91 \pm 0.27$  cmH<sub>2</sub>O\*sec\*kg<sup>10<sup>-2</sup></sup>/ml, respectively. There were no significant differences in these values among the groups.

As shown in Fig. 3, percent increase of Pao reached its maximum value of  $267 \pm 39$  % at 13 minutes after the inhalation in the control group (n=9), which was followed by decrease to  $245 \pm 32$  % at 18 minutes, and to  $222 \pm 25$  % at 23 minutes. In the group treated with 10 mg/ml of PSF, percent increase of Pao reached its maximum value of  $269 \pm 23$  % in 15 minutes, and decreased to  $253 \pm 23$  % at 18 minutes, and to  $210 \pm 22$  % at 23 minutes. In the group treated with 20 mg/ml of PSF, percent increase of Pao reached the maximum value of  $272 \pm 32$  % in 14 minutes, and thereafter, decreased to  $252 \pm 29$  % at 18 minutes, and to  $196 \pm 31$  % at 23 minutes. Recovery rate of Pao (percent change of the value at 23 minutes from that at 18 minutes) was  $5.9 \pm 2.4$  % in the control group,  $20.7 \pm 2.2$  % ( $p < 0.01$ ) in the group treated with 10 mg/ml of PSF, and  $23.4 \pm 4.7$  % ( $p < 0.01$ ) in the group treated with 20 mg/ml of PSF.

Fig. 4 shows changes of % Cdyn in the present experiment. The minimum value of % Cdyn of all the guinea pigs was  $10.3 \pm 0.3$  %, which was seen at  $14.3 \pm 0.5$  minutes after the antigen challenge. There was no significant difference in the minimum value and its appearance time among the three groups. On the other hand, recovery rates of Cdyn were  $14.6 \pm 1.9$  % in the control group,  $43.5 \pm 10.3$  % ( $p < 0.02$ ) in the group treated with 10 mg/ml of PSF, and  $52.0 \pm 9.5$  % ( $p < 0.01$ ) in the group treated with 20 mg/ml of PSF. Therefore, Cdyn recovered more rapidly in PSF-treated groups.

Changes in % 1/RL are shown in Fig. 5. The minimum value of % 1/RL of all the experimental animals was  $13.7 \pm 0.9$  %. There was no significant difference in the minimum value among these groups. Recovery rate of 1/RL was  $34.5 \pm 15.7$  % in the control group,  $39.5 \pm 5.5$  % (NS) in the group treated with 10 mg/ml of PSF, and  $102.4 \pm 15.7$  % ( $p < 0.01$ ) in the group treated with 20 mg/ml of PSF. Therefore, with regard to the change of 1/RL, there was no significant difference between the control group and the group treated with 10 mg/ml of PSF, but the recovery rate in the group treated with 20 mg/ml of PSF was significantly greater than that in the other groups.

## Influence of PSF inhalation on histamine-induced bronchoconstriction

Fig. 6 shows the influence of inhaling 20 mg/ml of PSF for 90 seconds on histamine-induced bronchoconstriction. No direct bronchodilative effect of PSF inhalation was observed in this experiment.

## Discussion

The guinea pigs used in this experiment constitute one of well characterized experimental models for bronchial asthma. The guinea pigs were passively sensitized with homocytotropic antiserum and pretreated with a high dose of diphenhydramine hydrochloride to block the bronchoconstriction mediated by endogenous histamine completely. By blocking the effect of histamine, dose-response and reproducibility are available, and hypersensitivity reaction occurs when the animals are challenged with an aerosol antigen. In the previous study of the inventor, this type of allergic bronchoconstriction was inhibited for the most part by continuous infusion of FPL55712, a selective inhibitor for the slow reacting substance of anaphylaxis (SRS-A), or by the pretreatment with inhalation of AS-35, a leukotriene receptor antagonist. From these facts, the bronchoconstriction following ovalbumine inhalation seen in the present experiment should be an allergic one mediated mainly by SRS-A.

A problem in the aerosolization of PSF is that only a limited quantity of the liquid can be deposited within lungs. Based on the data of Oyarzun MJ and Clements JA: Control of lung surfactant by ventilation, adrenergic mediators, and prostaglandins in the rabbit; Am Rev Respir Dis 1987; 117: 879-91, on total phospholipids recovered by lung lavage of rabbits (2.5 mg/g lung or 10 mg/kg body weight), we estimate that the amount of surfactant present in the lungs of a normal 400 g guinea pig is about 4 mg. As the total amount of the aerosolized Surfactant TA inhaled in this study is about 1 - 2 mg, and its deposition to the lungs and pulmonary bronchi was approximately 46 %, therefore, the amount of the deposition of Surfactant TA to the lungs and pulmonary bronchi was considered to be about 1/8 - 1/4 of the amount normally present in the lung. The deposition of inhaled aerosol particles in the inspirator is due to the mechanisms of inertial impaction, Brownian diffusion, and gravitational settling, and the bronchial and alveolar deposition fraction can be estimated by its particle size. In obstructive disease, the fraction of deposition by impaction

will increase. Since the mean particle size of PSF solution was about 3.6  $\mu\text{m}$  and there was no difference in the particle size among PSF, saline and albumin solutions, we can estimate that the deposition sites of these solutions will be equal and they will mainly deposit on the upper airway after the bronchoconstriction.

In the present experiment, the administration of an aerosolized exogenous PSF, i.e., Surfactant TA, restored, to some extent, the abnormal dynamic compliance (Cdyn) and the pulmonary resistance (RL) that accompanied endogenous SRS-A mediated bronchoconstriction. At the lower dose, PSF was effective only on the recovery of Cdyn, but at the higher dose, it was effective in the recoveries of both Cdyn and RL. As Cdyn and RL are recognized as parameters responding to lower airway and upper airway, respectively, the results suggest that inhaled PSF is more effective on peripheral airways than on upper airways. On the other hand, pretreatment with inhaled PSF did not influence the injected histamine-induced bronchoconstriction which shows that PSF has neither a direct bronchodilative effect nor a nonspecific bronchoconstrictive property.

On the other hand, if surface tension is higher in the airway closest to the alveolous, it can be considered too that the liquid in the alveoli moves to the airways at the beginning of exhalation. The liquid will narrow the air channel, causing more liquid to move into the airways so that collapse of the alveoli occurs. Administration of PSF prevents this collapse.

From the above results, it can be said that administering an exogenous PSF (Surfactant TA) is effective against allergic bronchoconstriction.

Surfactant TA contains 1 % of proteins mainly consisting of hydrophobic apoproteins. These proteins are important from the point of view of structure, surface activity and surface film formation, and therefore it is desirable that PSF contains proteins. However, a synthetic PSF which lacks apoprotein, such as Exosurf, has the activity although weak.

Test results on ALEC, Exosurf, Alveofact, Surfactant CK and Humansurf obtained in the same manner as Surfactant TA are shown in Figs. 7-21.

#### [Effects on asthma patients]

Respiratory function tests were performed in terms of forced vital capacity (FVC), forced expiratory volume in one second (FEV1.0), maximum mid expiratory flow (MMF),  $\Delta\text{N}_2$ , total lung capacity (TLC), residual volume (RV),  $\text{PaO}_2$  (arterial blood oxygen tension) and  $\text{PaCO}_2$  (arterial blood carbon dioxide tension) (Rinshokensa Gijutsu Zensho, Vol.9, Physiological function tests: 367-393, Igaku Shoin). As the measurement systems, a dry spirometer (FUDAC-60, Fukuda Co., Tokyo, Japan) and Blood Gas System 278 (Ciba Corning Diagnostics Co. Medfield, U.S.A.) were used.

FVC, FEV1.0 and MMF were calculated from the maximum flow volume curve obtained by making the patients inspire to the maximum and expire as rapidly as possible. The slopes of alveolar plateau expressing  $\Delta\text{N}_2$  was obtained from the nitrogen concentration-volume curves by single-breath nitrogen washout test. TLC were obtained by helium dilution closed circuit equilibration method. The RV/TLC value means the residual volume rate. The study was completed within 90 minutes and the tests were performed before and 20 minutes after administration of PSF.

Eleven allergic asthma patients having asthmatic attacks were divided into a PSF group (n=6) and a control group (n=5). The PSF group inhaled, with 100 %  $\text{O}_2$ , 10 mg of Surfactant TA suspended in 1 ml physiological saline by a jet nebulizer (Type 95-B nebulizer system, Hitachi Ltd., Tokyo, Japan). The nebulizer operated by 51 l/min jet flow obtained from 3.5  $\text{kgf/cm}^2$  compressed air.

The results of measurements are shown in Tables 1 and 2.

Table 1  
Respiratory function tests

Patient		FCV	FCV	FEV	FEV	MMF	MMF
		(b)	(a)	1.0 (b)	1.0 (a)	(b)	(a)
Group treated with PSF	1	3.74	4.31	1.67	2.13	0.61	0.83
	2	2.13	2.56	1.06	1.42	0.48	0.67
	3	2.40	2.71	0.86	1.23	0.30	0.48
	4	1.71	2.02	0.65	0.71	0.26	0.25
	5	2.12	2.66	1.06	1.30	0.47	0.50
	6	1.63	1.91	1.02	1.25	0.45	0.69
Control group	7	2.99	2.93	1.71	1.68	0.78	0.82
	8	2.13	2.31	1.66	1.66	1.42	1.07
	9	1.32	1.98	0.66	0.67	0.37	0.22
	10	1.07	1.02	0.62	0.58	0.24	0.21
	11	2.52	2.45	1.41	1.38	0.47	0.45



Patient		RV	RV	TLC	TLC	$\Delta N_2$	$\Delta N_2$
		(b)	(a)	(b)	(a)	(b)	(a)
Group treated with PSF	1	184.47	139.13	131.89	121.14	0.64	0.57
	2	227.42	210.48	127.45	130.55	2.86	2.41
	3	249.12	180.12	112.22	105.34	7.12	4.19
	4	162.80	141.06	103.80	88.73	1.93	1.45
	5	208.28	146.15	120.39	107.98	1.61	1.39
	6	91.91	73.53	84.49	78.88	2.16	1.38
Control group	7	165.57	167.21	130.47	129.95	1.28	1.88
	8	71.67	74.17	78.99	79.79	1.19	2.39
	9	147.59	185.56	89.39	104.13	1.22	2.56
	10	-	-	-	-	6.42	8.08
	11	212.30	232.40	130.42	134.50	3.51	3.78

Table 2

Blood gas test							
Patient		pH(b)	pH(a)	PaCO <sub>2</sub> (b)	PaCO <sub>2</sub> (a)	PaO <sub>2</sub> (b)	PaO <sub>2</sub> (a)
Group treated with PSF	1	7.430	7.45	42.5	37.6	53.0	64.3
	2	7.382	7.376	39.1	35.6	72.1	72.9
	3	7.440	7.434	38.0	37.8	68.7	72.6
	4	7.430	7.421	44.5	43.8	74.4	98.2
	5	7.449	7.423	32.6	36.5	68.0	72.0
	6	7.404	7.424	36.0	33.1	67.1	77.2
Control group	7	7.405	7.409	33.5	33.1	73.2	70.5
	8	7.425	7.420	32.7	30.1	74.7	73.2
	9	7.510	7.500	39.3	39.6	55.7	54.1
	10	7.337	7.368	50.8	48.5	50.2	52.7
	11	7.360	7.356	39.1	39.8	72.3	70.5

In the respiratory function tests and blood gas test, the effect of administering PSF is expressed as a percentage according to the following formula and the results are shown in Table 3.

$$\frac{[\text{RF}(\text{after PSF}) - \text{RF}(\text{before PSF})]}{\text{RF}(\text{before PSF})} \times 100$$

(RF means respiratory function data)

Table 3

	FVC	FEV1.0	MMF
PSF group	18.2 ± 1.2	26.5 ± 4.7	31.9 ± 10.4
control group	9.7 ± 10.3	-1.8 ± 1.3	-15.4 ± 8.0
	RV	TLC	RV/TLC
PSF group	-20.5 ± 3.5	-7.2 ± 2.3	-14.2 ± 3.7
control group	9.9 ± 5.6	-5.1 ± 3.9	3.5 ± 1.5
	$\Delta N_2$	PaCO <sub>2</sub>	PaO <sub>2</sub>
PSF group	-23.7 ± 5.1	-3.1 ± 3.5	13.5 ± 4.8
control group	58.2 ± 20.3	-2.2 ± 1.8	-1.2 ± 1.6

In the control group, FVC, FEV1.0, MMF and PaO<sub>2</sub> were almost unchanged although  $\Delta N_2$  increased significantly. In the PSF-administered group, FVC, FEV1.0, MMF, PaO<sub>2</sub> and  $\Delta N_2$  were markedly improved in all patients.

Moreover, the means of TLC and RV had no significant change in the control group, but were significantly decreased after inhalation in the PSF group. The RV/TLC was also decreased in the PSF group.

This means that PSF exhibits the effect of bronchodilation on constricting bronchioles by stabilizing the bronchioles, causing maximum ventilation on the peripheral alveoli and preventing air trapping, and as a result inhibits asthmatic symptoms.

Blood gas analysis test revealed no significant difference in PaCO<sub>2</sub> between both groups. In addition, PaO<sub>2</sub> was significantly increased after treatment in the PSF group but had no change in the control group. This suggests that PSF improves incorporation of oxygen into the alveoli.

In all patients of the PSF group, asthmatic attacks and symptoms were relieved. On the other hand, in 5 patients of the control group, these were not changed or worsened.

As is stated, it can be concluded that the drug containing PSF as effective ingredient is a useful antasthmatic.

## [Acute toxicity test]

To male ICR mice aged 5 weeks and male Wister rats aged 5 weeks, Surfactant TA was administered by oral and intraperitoneal route to obtain LD<sub>50</sub>s. In the mice, the LD<sub>50</sub> was 3 g/kg or more by oral route and 2g/kg or more by intraperitoneal route. Similarly, in the rats, LD<sub>50</sub> was 4 g/kg or more by oral route and 2.5 g/kg or more by intraperitoneal route.

## [Subacute toxicity test]

To mature Wister rats, Surfactant TA was intraperitoneally administered at a dose of 500 mg/kg for one month. There were no changes in body weight nor findings by gross and histological observations of the lungs or the other main organs in the rats one month later. Moreover, no biological abnormalities caused by heterologous protein were found.

## [Method of use and dosage]

The antasthmatic provided by the present invention contains 1 - 50 mg of PSF as one dose for an adult. As to use, the above-mentioned dose is suspended in an electrolyte solution such as water or physiological saline to obtain a concentration of 0.1 - 100 mg/ml, and injected or sprayed into the air way before and after onset of asthma. As the frequency of administration, 1 - 10 times are adequate. Depending on patients' symptoms or combined treatments, the above-mentioned dosage, method of use and frequency may be changed suitably.

As necessary, the antasthmatic of the invention may contain pharmaceutical additives including stabilizer, preservative, isotonicizing agents, buffers or suspensions, or bactericides. As dosage form, liquid or powder used by suspending on need is appropriate. This drug is packed in an airtight container such as a vial and an ampule, and preserved as an aseptic preparation.

## Claims

1. An antasthmatic containing a PSF as an effective ingredient.
2. The antasthmatic according to claim 1, wherein the PSF contains 40 % or more of phospholipids as a whole.
3. The antasthmatic according to claim 2, wherein a main component of the phospholipids is phosphatidyl choline or choline phosphoglyceride.
4. The antasthmatic according to claim 1, wherein the PSF is one selected from the group consisting of Surfactant TA, Surfactant CL, Synthetic Surfactant X1, Synthetic Surfactant X2, Surfactant CK, Alveofact, Humansurf, Exosurf and ALEC.

FIG. 1




FIG. 2






FIG. 3



# FIG. 4

A



B





FIG. 5

A



B




FIG. 6






FIG. 7




FIG. 8





FIG. 9







FIG.10



## FIG. II

A



B





FIG.12

A



B




FIG. 13





FIG. 14

A



B








FIG. 16





FIG. 17

A



B





FIG. 18

A



B




FIG. 19





FIG. 20

A



B






FIG.21

A



B



# INTERNATIONAL SEARCH REPORT

International Application No. PCT/JP91/00664

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int. Cl <sup>5</sup> A61K37/22		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched :		
Classification System	Classification Symbols	
IPC	A61K37/22, A61K35/42, A61K31/685	
Documentation Searched other than Minimum Documentation to the extent that such documents are included in the fields searched *		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT</b> †		
Category *	Citation of Document, †† with indication, where appropriate, of the relevant passages †‡	Relevant to Claim No. †‡
A	JP, A, 64-63526 (Kiegi Pharmaetichi S.p.A.), March 9, 1989 (09. 03. 89), Claim & EP, A, 286011	1-4
A	JP, A, 60-237023 (Volksaigenelbetoriip, Alzunimitterwelge, dressden), November 25, 1985 (25. 11. 85), Claim & EP, A, 145005	1-4
A	JP, A, 58-183621 (Teijin Ltd.), October 26, 1983 (26. 10. 83), Claim (Family: none)	1-4
A	JP, A, 58-164513 (Teijin Ltd.), September 29, 1983 (29. 09. 83), Claim (Family: none)	1-4
<p>* Special categories of cited documents: †§</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"S" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
July 10, 1991 (10. 07. 91)	July 29, 1991 (29. 07. 91)	
International Searching Authority	Signature of Authorized Officer	
Japanese Patent Office		